Veterinarians Share Experiences Through Immersive NOBIVAC® Global Exchange Program

Program Offers Opportunities to Collaborate Across Countries

MADISON, N.J., September 11, 2015 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) is proud to announce the return of the NOBIVAC® Global Vet Exchange Program. Twenty-four veterinarians from eight countries will have the opportunity to visit clinics across the globe and share their knowledge and experience in veterinary care.

This year, talented veterinarians from the United States, Sweden, Denmark, the United Kingdom, Germany, Italy, China and Japan will participate in the program by immersing themselves in each other’s clinics for one week. During this time, the veterinarians will be able to observe and discuss new approaches to patient care and clinic management, helping them identify best practices that they can bring home. To share the experience with a wide audience of veterinarians, the participating veterinarians will document their trips through blog entries and videos on

“The NOBIVAC Global Vet Exchange is an incredible opportunity for international collaboration,” said Dr. Eleonor Shelburne from Northampton Veterinary Clinic, a participant in the program from Northampton, MA, USA. “I look forward to discovering the similarities and differences between my host clinic and my own practice, and believe the experience will spark important discussions that can benefit both.”

In 2014, ten veterinarians participated in the inaugural year of the NOBIVAC Global Vet Exchange, representing the United States, the United Kingdom, the Netherlands, China and Japan. One of the participating veterinarians, Dr. Roeland Wessels of Nijmegen, Netherlands traveled to Japan through the Exchange.

“In the almost twenty years that I’ve been a veterinarian, this was absolutely one of the most remarkable weeks in my professional career,” said Dr. Wessels. “My number one observation from my week in Japan would be that we are more similar than we are different, because our profession is the same – it’s all about the bond between animals and humans.”

“With the NOBIVAC® Global Vet Exchange, we aim to facilitate connections that will have a lasting impact on companion animal wellbeing,” said Ingrid Deuzeman, director, Global Marketing, Merck Animal Health. “While participants will see firsthand how animal care differs from country to country, we hope they will also discover how veterinarians worldwide are united by one common mission: to advance the health of animals.”

To learn more about the NOBIVAC Global Vet Exchange and learn how you can participate in the exchange, visit

About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn and Twitter.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA  
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (